StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

Equities researchers at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a report issued on Saturday. The firm set a “sell” rating on the stock.

Separately, Roth Mkm reiterated a “buy” rating and set a $20.00 price target on shares of Bio-Path in a research report on Monday, July 8th.

Bio-Path Trading Down 7.3 %

Shares of NASDAQ:BPTH opened at $0.89 on Friday. The company’s 50-day moving average price is $1.37 and its 200 day moving average price is $2.51. Bio-Path has a fifty-two week low of $0.88 and a fifty-two week high of $21.60.

Bio-Path (NASDAQ:BPTH) last released its quarterly earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.38. During the same period in the prior year, the firm posted ($10.60) EPS. As a group, research analysts forecast that Bio-Path will post -6.2 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC bought a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path at the end of the most recent reporting period. Institutional investors and hedge funds own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.